STOCK TITAN
  1. Home
  2. News
  3. TRYPF

Tryp Therapeutics Inc - TRYPF STOCK NEWS

Welcome to our dedicated news page for Tryp Therapeutics (Ticker: TRYPF), a resource for investors and traders seeking the latest updates and insights on Tryp Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tryp Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tryp Therapeutics's position in the market.

News
Tryp Therapeutics Provides Update on Plan of Arrangement With Exopharm Limited and Announces Voluntary Trading Halt
Rhea-AI Summary
Tryp Therapeutics, Inc. provides an update on the plan of arrangement with Exopharm , with shareholders' approval and pending ASX approval. The voluntary trading halt is announced.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.26%
Tags
none
-
News
Tryp Therapeutics Announces 99.92% Votes Cast by Shareholders in Favor of Arrangement Agreement at Annual General and Special Meeting of Securityholders, and Receipt of Final Order
Rhea-AI Summary
Tryp Therapeutics, Inc. announces overwhelming approval of arrangement with Exopharm Limited at securityholders meeting. The special resolution for the arrangement was approved by 99.92% of Tryp shareholders, with a total of 37,738,906 common shares voted. The closing of the arrangement is pending final court, stock exchange, and regulatory approvals, expected in late March 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.26%
Tags
none
-
News
Tryp Therapeutics Obtains Interim Order for Plan of Arrangement and Provides Details of Shareholder Meeting
Rhea-AI Summary
Tryp Therapeutics, Inc. has obtained an interim order of the Supreme Court of British Columbia in connection with the proposed arrangement between Tryp and Exopharm Limited. The meeting for Tryp securityholders to consider and vote on a special resolution approving the arrangement is scheduled to be held on March 8, 2024, in Toronto, Ontario. Tryp will be mailing meeting materials to securityholders, and an application for the final order of the Court is expected to take place on or before March 8, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.07%
Tags
none
News
Tryp Therapeutics and Exopharm Limited Secure Pivotal 2 Cent Waiver From ASX
Rhea-AI Summary
Tryp Therapeutics, Inc. announced a pivotal 2 cent waiver granted by the Australian Securities Exchange, leading to an amendment to its arrangement agreement with Exopharm Limited. Under the revised terms, Exopharm will acquire all issued and outstanding common shares of Tryp, in exchange for 3.616 ordinary shares of Exopharm for each Tryp share, with a consolidation of Exopharm shares before completing the transaction. Holders of convertible securities of Tryp will receive replacement securities of Exopharm with similar economic terms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.14%
Tags
none
-
News
Tryp Therapeutics Announces Significant Milestone in Its Clinical Trial Program for Trp-8803 (IV-infused Psilocin)
Rhea-AI Summary
Tryp Therapeutics, Inc. (TRYP) has received approval from the Human Research Ethics Committee in Australia to commence the Phase 1 clinical trial of TRP-8803, an IV-infused psilocin for diseases with high unmet medical needs. The trial aims to optimize doses and infusion rates of IV-administered psilocin to achieve targeted blood levels and collect real-time EEG data from human volunteers. The company is also making strides with its TRP-8802 clinical trial for irritable bowel syndrome patients, with patient dosing expected in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.84%
Tags
clinical trial
-
News
Tryp Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial for the Treatment of Fibromyalgia at The University of Michigan
Rhea-AI Summary
Tryp Therapeutics Inc. (TRYP) announces the dosing of the first patient in a Phase 2a clinical trial for TRP-8802, a precursor to their lead drug candidate TRP-8803, designed to treat fibromyalgia and other neuropsychiatric disorders. The company aims to improve upon the limitations of oral psilocybin and provide relief to patients suffering from chronic pain.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.61%
Tags
clinical trial
News
Tryp Therapeutics Inc. Announces Signing of Definitive Agreement with Exopharm Limited
Rhea-AI Summary
Tryp Therapeutics Inc. (CSE:TRYP), a clinical-stage biotechnology company, has entered into an arrangement agreement with Exopharm Limited for the acquisition of all of its issued and outstanding common shares in consideration of the issuance of 4.52 ordinary shares in the capital of Exopharm for each one Tryp Share. The purchase price of CAD$0.08 represents a 78% premium to the closing price of $0.045 and a 112% premium to the 20-day volume weighted price of $0.0378 per Tryp Share on December 8, 2023. Tryp shareholders are expected to receive 4.52 Exopharm Shares for each one Tryp Share held, representing an aggregate transaction value of approximately $12.8 million. The combined entity is expected to relist on the Australian Securities Exchange in Q1 2024 subject to approvals and raising a minimum of AUD$6,000,000 under a public offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.33%
Tags
none
-
News
Tryp Therapeutics Announces Closing of Oversubscribed Private Placement of Unsecured Convertible Notes for Gross Proceeds of AUD$3,215,000
Rhea-AI Summary
TRYP Therapeutics Inc. (CSE:TRYP) Announces Successful Closing of Oversubscribed Private Placement of Unsecured Convertible Notes
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.03%
Tags
none
-
News
Tryp Therapeutics Announces Closing of Private Placement of Unsecured Convertible Debentures for Gross Proceeds of AUD$175,000
Rhea-AI Summary
Tryp Therapeutics Inc. announces the closing of its private placement of unsecured convertible debentures to its CEO for AUD$175,000.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
none
News
Tryp Therapeutics Announces Jason Carroll as New Chief Executive Officer
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
none
Stock TRYPF logo
Tryp Therapeutics Inc

OTC:TRYPF

TRYPF Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

TRYPF Stock Data

3.63M
51.34M
0.7%
Medicinal and Botanical Manufacturing
Manufacturing
Link
Canada
Kelowna